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Abstract
Background. Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas with high
metastatic rates and poor overall patient survival. There are currently no effective therapies, underscoring the
pressing need to define the molecular etiologies that underlie MPNST progression. The aim of this study was to
examine clonal progression and identify the molecular events critical for MPNST spread.
Methods. In two patients with temporally and spatially distinct metastatic lesions, we employed whole exome
sequencing (WES) to elucidate the genetic events of clonal progression, thus identifying the molecular events critical for MPNST spread.
Results. First, we demonstrated shared clonal origins for the metastatic lesions relative to the primary tumors,
which were maintained throughout the course of MPNST progression, supporting the conclusion that cancer cells
with metastatic potential already exist in the primary neoplasm. Second, we discovered TRIM23, a member of the
Tripartite Motif family of proteins, as a regulator of MPNST lung metastatic spread in vivo.
Conclusions. The ability to track the genomic evolution from primary to metastatic MPNST offers new insights into
the sequence of genetic events required for tumor progression and has identified TRIM23 as a novel target for future study in this rare cancer.

Key Points
• Cancer cells contributing to metastasis and reduced survival are present early in disease
evolution.
• TRIM23, a seminal member of the TRIM family, plays a role in enhancing metastatic
behavior.
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Importance of the Study

Neurofibromatosis type 1 (NF1) is a common cancer predisposition syndrome, affecting approximately 1 in 3,000 individuals worldwide.1 All individuals with NF1 are born with
a germline mutation in one copy of their two NF1 tumor
suppressor genes, but develop benign tumors following somatic inactivation of the remaining NF1 allele.2 Although benign tumors predominate in children with NF1, adults with
NF1 are at risk for malignancy, most commonly malignant
peripheral nerve sheath tumors (MPNSTs). These Schwann
cell-derived neoplasms metastasize widely to the lung and
bone, and the majority of patients die from metastatic disease within 5 years of initial diagnosis, even after surgery,
radiation, and chemotherapy.
Given the elevated frequency of MPNSTs (10%–13%
adults3) and their younger age of onset (~3rd decade of
life4,5), NF1 has emerged as a tractable model system to
define the molecular etiologies for MPNST pathogenesis,
as these cancers most often arise from benign precursor
lesions (plexiform neurofibromas) with biallelic NF1 gene
inactivation. Importantly, transformation to cancer requires additional genetic alterations involving other genes,
such as TP53, CDKN2A, and EED/SUZ12.6 Although numerous laboratories have focused on understanding the
molecular evolution of MPNST from their benign counterparts, very few studies have attempted to characterize the
intratumoral heterogeneity as it relates to MPNST metastasis.7,8 In an effort to define the genomic alterations important for tumor progression and explore intratumoral
heterogeneity, we employed next generation sequencing
technology to analyze MPNSTs from two patients with NF1
who each developed temporally and spatially distinct metastases over a period of 2–3 years.

Methods
Study Approvals
Blood, tumor, and other tissues were obtained from individuals diagnosed with NF1 according to established
criteria9 and treated at Washington University/St. Louis
Children's Hospital NF Clinical Program (St. Louis, MO). All
human tumor samples were collected under an approved
IRB protocol (#201203042) at Washington University, and
all patients were appropriately consented. The Institutional

the molecular events critical for metastatic
progression. This analysis led to the identification of point mutations and copy number
alterations in TRIM23 within the metastatic lesions. Additionally, we found that increased
expression of nuclear TRIM23 correlated with
worse overall survival in patients. Furthermore,
Trim23 knockdown in murine NPcis MPNST
cell lines resulted in a decreased propensity
for metastasis in vivo, establishing TRIM23 as a
potential candidate for further study.

Animal Care and Use Committee of Washington University
has reviewed and approved our protocol for experiments
utilizing animals. Animals were treated in compliance with
IACUC policies.

Patient Sample Preparation and Sequencing
Whole-exome sequencing was performed on tumor and
matched normal DNA. Tumor DNA samples were obtained
from formalin-fixed paraffin-embedded (FFPE) blocks
or frozen tissue (when available) obtained at surgical resection or biopsy. Normal paired DNA was isolated from
peripheral blood obtained by phlebotomy. The original
samples were submitted to Otogenetics Corporation
(Atlanta, GA) for human exome capture and sequencing.
Genomic DNA (gDNA) was extracted from blood or frozen
tissue using Qiagen DNeasy Blood & Tissue kit (Qiagen
Ca#69506). Briefly, gDNA was subjected to agarose gel
and OD ratio tests to confirm the purity and concentration
prior to Bioruptor (Diagenode, Inc., Denville, NJ) fragmentation. Fragmented gDNAs were tested for size distribution and concentration using an Agilent Tapestation 2200
and Nanodrop. Illumina libraries were made from qualified fragmented gDNA using SPRIworks HT Reagent Kit
(Beckman Coulter, Inc. Indianapolis, IN, catalog# B06938)
and the resulting libraries were subjected to exome enrichment using SureSelectXT Human All Exon version 5
(Agilent Technologies, Wilmington, DE, catalog# 5190-6210)
following manufacturer's instructions. Enriched libraries
were tested for enrichment by qPCR and for size distribution and concentration by an Agilent Bioanalyzer 2100. The
samples were then sequenced on an Illumina HiSeq2500,
which generated paired-end reads of 125 nucleotides
(nt). Data were analyzed for data quality using FASTQC
(Babraham Institute, Cambridge, United Kingdom).

Alignment, Variant Calling, and Bioinformatics
Analysis
Sequence reads were mapped to the human reference
genome (GRCh37/hg19) using Novoalign tool v3.02.06
(http://www.novocraft.com/products/novoalign/) followed
by marking and removing PCR duplicates by PICARD
tools v2.4.1 (http://broadinstitute.github.io/picard/). Local
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Malignant peripheral nerve sheath tumors
(MPNSTs) are aggressive soft tissue sarcomas
with a high metastatic potential. Despite aggressive therapy, the 5-year overall survival
is dismal. As such, there is a pressing need
to understand the genomic mechanisms that
underlie metastatic progression in order to
design rational therapies. We leveraged wholeexome sequencing of the tumors from two
patients with sequential metastatic lesions to
better define tumor clonality and to identify
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Hematoxylin and eosin–stained sections were retrieved
and were reviewed by a bone and soft-tissue sarcoma
pathologist (JC) to confirm the diagnosis. Additional
formalin-fixed paraffin-embedded sections were obtained
from the patient blocks at Washington University in St.
Louis along with previously described tissue microarrays generated at UCSF.4 Immunohistochemical stain
for TRIM23 (ThermoFisher, PA5-34624, 1:150, rabbit polyclonal) was performed with appropriate positive and
negative controls. Slide reviewers were blinded to the
patients' clinical status. Nuclear staining for TRIM23 was
evaluated for staining intensity (0 = negative, 1 = weak,
2 = moderate, and 3 = strong) and percentage of positive tumor cell nuclei (0 = 0%, 1 = 1%–24%, 2 = 25%–49%,
3 = 50%–74%, and 4 = 75%–100%).16 For survival analysis, samples were classified as “low” if the staining intensity was 0 or 1. Likewise, samples were classified as
high if the intensity was 2 or 3. Immunohistochemistry
for histone 3 lysine trimethylation (H3K27 me3) was performed using rabbit monoclonal antibodies (C36B11, 1:50
dilution; Cell Signaling Technology, Danvers, Mass) and
Trisethylenediaminetetraacetic acid (EDTA) antigen retrieval. Tumors with nuclear staining in <5% of the tumor
cells, in the presence of an internal positive control
(e.g., endothelial cells), were scored as having a loss of
H3K27me3. Immunohistochemical staining for Cleavedcaspase 3 at 1:500 (Cell Signaling Technology, Danvers,
MA) with citrate antigen retrieval or prediluted Ki67 (790–
4286; Ventana) with CC1 buffer (950- 124, Ventana) antigen
retrieval was performed on subcutaneous tumor sections
and the number of cells in five high power fields were
counted by three blinded reviewers.

Cell Culture, Transduction, and Immunoblot
Analysis
Murine MPNST tumor lines established from C57BL6/J
Nf1+/−;Trp53+/− (NPcis) expressing GFP-Luciferase17 were
used for the in vitro, and in vivo MPNST tumor growth experiments. Cells were transduced with either lentiviral control shLacZ (Genome Institute at Washington University)

RNA Extraction and Quantitative RT–PCR
Total RNA was extracted from NPcis cells infected
with shLacZ or shTrim23 using TRIzol according to
manufacturer's instructions (ThermoFisher Cat. #15596026).
Reverse transcription reactions were performed with
Superscript III (Invitrogen) according to manufacturer's
protocol. Real-Time PCR reactions were executed using
CFX96 Real-Time PCR Detection System (BioRad) and detected using PowerUp SYBR Green (Applied Biosystems;
100029284). The following primers were used:
Gapdh forward, 5′-ATGACATCAAGAAGGTGGTG-3′;
Gapdh reverse, 5′-CATACCAGGAAATGAGCTTG-3′;
Trim23 forward, 5′-ATACAGGTTCTGGAGTGTGG-3′;
Trim23 reverse, 5′-CCTGAGTCTCCTAGGTCTGTTAC-3′
Analysis was performed on Bio-Rad CFX Manager
Software (BioRad 2017).

In Vitro Assays
Cells were counted using the Countess Automated Cell
Counter (Invitrogen), plated in 96-well plates (~ 15,000 cells/
well), and allowed to grow overnight. For proliferation assays, cells were plated in phenol-red free DMEM with 10%
FBS. Cells were imaged every hour for 48 hours using the
Incucyte FLR imaging system (Essen Bioscience, Ann Arbor,
MI) and analyzed for quantitation using Incucyte ZOOM
Analysis Software (Essen Biosciences). Phase images were
used to determine percent confluence and subsequent
wells were normalized to initial confluence. For clonogenic
assays, control (shLacZ), and shTRIM23 Cell lines (1,2,3)
were seeded at 200 cells/well in a 6 well dish (triplicates)
in 3-mL DMEM medium. An initial image was taken 24
hours after plating (0 h) and allowed to grow for 2 weeks
where a final image was taken (2 wk) using the IncuCyte
system (Sartorius, Ann Arbor, MI). For quantification of colonies, using the image analysis software provided with the
Incucyte system, cell masks were calculated for each respective well to quantify confluency at each time point.
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Immunohistochemical Evaluation

or separate lentiviral shRNAs targeting Trim23 (Sigma;
TRCN0000308323, TRCN0000308321, TRCN0000308320).
The cell line exhibiting the best knockdown, as determined by Western blot and mRNA analysis, was selected
and expanded for subsequent experiments (Sigma
TRCN0000308323). No mycoplasma contamination was detected in any cell lines and cells were used within 3–7 passages from thawing. Western blots were performed from
lysed cell pellets using 1%NP-40 lysis buffer supplemented
with protease inhibitors. Protein separation and detection
were performed using an automated capillary electrophoresis system (Simple Western system and Compass software; ProteinSimple). Wes Separation Capillary Cartridges
for 12–230 kDa were used for detection and internal Total
Protein Detection were used for quantitation controls according to manufacturer instructions. TRIM23 antibody
(dilution 1:50) was used for signal detection along with an
HRP-conjugated secondary anti-rabbit antibody, and was
visualized using ProteinSimple Compass software.

Neuro-Oncology
Advances

realignment around insertions/deletions was achieved by
Genome Analysis Toolkit (GATK) v3.6-0.10 Somatic singlenucleotide variants were identified using Mutect v1.1.411
and detection of insertions and deletions used Indelocator
(https://www.broadinstitute.org/cancer/cga/indelocator).
The tools compared each individual primary tumor or metastatic sample to the matched germline sample. Variants
were then annotated using wAnnovar (http://wannovar.
wglab.org/)12 which uses information from publicly available databases including 1000 genome, ExAC, dbSNP,
COSMIC, and ClinVar. Copy Number Variants were detected and plotted using CNVkit13 and recurrent copy
number changes were identified using GISTIC.14 Clonality
was addressed using SciClone.15 After identifying targets
of interest, Kaplan Meier Curves were generated using
GEPIA (http://gepia.cancer-pku.cn/) on the TCGA RNA-seq
expression dataset for a 95% confidence interval.
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Immunofluorescence
Cells were plated at low density on chamber slides
(MilliporeSigma) and fixed with 4% paraformaldehyde,
permeablized for 5 min at 4°C with 0.1% Triton-X100. Cells
were stained with previously reported TRIM23 antibody
(1:150; 4°C overnight) and β-actin (Santa Cruz; sc-47778;
1:500; 37°C 45min) and fixed with ProLong Gold Antifade
Mountant with DAPI (ThermoFisher; P36930).

Subcutaneous tumors were performed by injecting 1 × 105
cells into the medial flank 4-week-old male B6N-Tyrc-Brd/
BrdCrCrl mice (Charles Rivers)17 using JW23.3-shLacZ and
JW23.3-shTrim23-3405 tumor cells (n = 5 mice/group) imaged at days 4, 8, 14, 21, and 28. The metastatic model
involved injecting 1 × 105 cells intraventricularly into 3-weekold anesthetized male B6N-Tyrc-Brd/BrdCrCrl mice for imaging at days 2, 5, 9, 12, and 16. Each experiment consisted of
5 mice per group and each experiment was repeated to validate the results. Luciferase signal was measured in photon
flux and was quantitated using automatic and constant ROIs
for subcutaneous and intraventricular models respectively.

Statistics
Kaplan–Meier survival curves based on TRIM23 patient
immunohistochemistry was analyzed using GraphPad Prism
Version 7.03. The association between TRIM23 protein expression and H3K27 me3 status was assessed by chi-square test.
Kaplan–Meier survival curves were generated for overall survival by H3K27 me3 protein expression groups in MPNST.
Patients were censored by date of death (Social Security Death
Index, expiration note in chart or obituary) or date of last follow-up. Overall survival is defined as date from diagnosis to
date of death by any cause. The survival difference between
groups was compared using the log-rank test. Statistical analyses were performed with GraphPad Prism Version 7.03 and
SAS (version 9.4; SAS Institute, Cary, NC). Statistical analyses for qRT–PCR analyses were performed using GraphPad
Prism. Bar graphs are presented as the mean +/− SEM, and the
Students t-test was used for statistical significance. Statistical
significance was determined for all Incucyte assays and all in
vivo experiments using one-way and two-way ANOVA analysis, respectively, on GraphPad Prism.

Results and Discussion
Clonal Origins of MPNST

Genomic Analysis Identifies TRIM Family
Members as Potential Drivers of Metastasis

WES was performed on resection and biopsy materials
from the primary tumor and associated metastatic lesions
from two patients with NF1, established using NIH consensus diagnostic criteria18 (Figure 1A). Samples from patient A included a right thigh primary MPNST at age 38, as
well as a right lower lobe lung metastasis at age 38 and a
right humeral bone metastasis at age 39, whereas those
from patient B included a left thigh primary MPNST at age
20, a right upper lobe lung metastasis at age 21 and a right

To understand the importance of MPNST clonal diversity,
nonsynonymous exonic SNP mutations were examined
in both patient tumors. Point mutations were filtered by
known polymorphisms, based on prevalence in the population using 1000 genomes and COSMic. Only mutations
with a VAF > 0.03 were grouped within each sample and
then overlapped for each patient (Figure 2A and B). Using
these stringent criteria, no point mutations were shared
across all samples. However, mutations in the TRIM family
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In Vivo Studies

lower lobe lung metastasis at age 22 (Figure 1B and C,
upper panels; Supplementary Figure 1 [See online supplementary material for a color version of this figure.]). NF1
mutation status and the presence of co-existing mutations
associated with malignant transformation, including copy
number loss at the CDKN2A locus, were demonstrated in
both MPNSTs (Supplementary Figure 2 [See online supplementary material for a color version of this figure.]).
To investigate MPNST clonality, samples were clustered
based on variant allele frequencies (VAF) within each tumor
using SciClone, and compared against the other tumor
samples within the same patient (Figure 1B and C, middle
panels). Unexpectedly, we saw no emergence of a dominant clone enriched within the metastatic lesions. Rather,
all of the clusters fell close to the identity line, suggesting
similarity in the genomic mutation distribution within each
patient. Next, the density of VAFs across the genome was
examined for each tumor (Figure 1B and C, bottom panels).
Genes mutated at similar rates show greater density on
the plot. In patient A, mutational densities were grouped at
high VAF counts in both the primary and lung metastasis,
again supporting a shared genomic mutational profile.
Read counts within the bone metastasis were unusually
low, likely due to artifact from the decalcification process,
thus precluding further analysis. However, in patient B,
the primary tumor contained a subset of genes with VAFs
between 20% and 60% and a smaller set of genes with a
VAF between 85% and 100%. Between the primary tumor
and the metastases, there was a right shift in density,
suggesting enrichment of some clones. Nonetheless, the
overall similarity of the distribution implied a shared genomic profile as the cancer evolves from primary tumor to
metastatic lesion. These data argue that the primary tumor
is polyclonal, and the subsequent metastatic lesions share
the clones already present in the primary tumor. This observation is consistent with other recent reports, which
demonstrate polyclonal metastases.19,20 Given the genomic instability present in these rapidly dividing cancer
cells, this clonality suggests more similarities among the
samples than would have been predicted. Taken together,
it is likely that the cancer cells that drive MPNST metastasis exist in the primary tumor, supporting the notion that
cancer progression may be targetable early during disease
evolution. Moreover, the variation of clonal ratios in each
MPNST sample may explain the differential responses of
metastatic lesions to chemotherapy, suggesting that therapies for these deadly cancers may require a combination
of distinct anti-neoplastic agents.
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Figure 1. Patient characteristics and establishing clonal origin of metastases within MPNSTs. (A) Patient characteristics at time of diagnosis and
overall disease progression. (B, C Upper) MPNST Treatment progression for patients A and B after diagnosis. Three spatially distinct tumor samples
were aligned to normal blood control from each individual. (B, C Middle) Still-frame of a 3-dimensional plot of VAF clusters of genomic signatures in
copy number neutral regions compared across samples within a patient. (B,C Bottom) Kernel density plots of proportion of mutations at each VAF
across genome. Densities were summated over all clusters for each cluster/component. Line color based on predicted ploidy (posterior predictive
densities) of the cell: one (dark grey), two (green), or three (yellow).
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PRTFDC1
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ZNF646
NLGN4X
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FOXP3
IKZF1
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Figure 2. Genomic mutations over the course of metastatic MPNST. (A, B) Nonsynonymous exonic somatic called variants in each sample.
Variants in the primary tumors are depicted in the blue circles. Mutations in the bone metastasis are depicted in the yellow circle. Mutations in the
lung metastases are depicted in the red circles. TRIM genes, including TRIM23, mutated in the samples have been bolded.
  

of proteins, a class of E3-Ubiquitin ligases, were present
at higher rates in all of the metastatic samples. TRIM proteins are ubiquitously expressed in normal tissue, where

they have cell type- and context-dependent functions.
However, relevant to MPNST, TRIM proteins have been implicated as both positive and negative regulators of cancer
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TRIM23 Low Expression

Figure 3. Identification of TRIM Family as potential drivers of progression and survival. (A) Kaplan–Meier survival curves for TRIM23 expression
in sarcoma (SARC), glioblastoma (GBM), and breast carcinoma (BRCA) from TCGA GEPIA database. (B) Kaplan–Meier survival curves for TRIM23
expression from a cohort staining analysis of MPNST patients from Washington University in St. Louis and UCSF (P = .15; n = 39). (C) Representative
examples of TRIM23 staining in MPNST.
  

  
Table 1.

TRIM23 expression in H3K27 staining

TRIM23 Expression
Intensity

H3K27 Staining
Loss

High

Total

Low

13

8

21

61.9%

38.1%

14

7

66.67%

33.33%

27

15

High
Total

21
42

  
progression.21–23 In light of recent reports demonstrating
ubiquitination in cancer progression and metastasis,24 we
pursued copy number alterations in the TRIM family members in all of the samples. Gains were called when log2
> 1.0 and losses were called when log2 < −1.0. Of the 61
TRIM family members, 14 members showed significant

copy number alterations across samples (Supplementary
Figure 3 [See online supplementary material for a color
version of this figure.]). TRIM23 is particularly compelling,
as it is the only member of the family with GTP binding
activity,22 and was the only TRIM family member identified
in both point mutation and copy number analysis. Next,
we queried a set of high-grade malignancies, which occur
at an increased frequency in patients with NF1, including
glioblastoma (GBM), breast cancer, and other sarcomas
(SARC). Using the cancer genome atlas (TCGA) database
available through the GEPIA portal, we analyzed the correlation between TRIM23 expression and overall survival25
and found that TRIM23 expression was associated with
worse overall survival in this combined data set (Figure 3A,
P = .0000064). Next, we examined TRIM23 expression in
forty MPNSTs from Washington University and UCSF, and
employed Kaplan–Meier analysis to define the relationship
between TRIM23 expression and overall survival. Although
patients with higher TRIM23 expression trended toward
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To assess the potential functional significance of Trim23 expression in MPNST pathogenesis, we first evaluated protein
expression in three murine Nf1/Tp53-mutant NPcis MPNST
cell lines engineered to express luciferase.17 All three lines
had varying levels of Trim23 expression (Supplementary
Figure 5 [See online supplementary material for a color
version of this figure.]). We specifically chose the line with
the highest Trim23 expression for subsequent experiments
(Supplementary Figure 5A and B [See online supplementary material for a color version of this figure.]). This line is
also the most aggressive of the three lines (Supplementary
Figure 5C–F [See online supplementary material for a color
version of this figure.]). Three shRNA constructs were
used to knockdown Trim23 expression (Figure 4A and B;
Supplementary Figure 6A [See online supplementary material for a color version of this figure.]) and utilized for in
vitro experiments. The line with the most robust knockdown was chosen for in vivo testing. There was no change
in MPNST cell proliferation following Trim23 knockdown in
vitro (Figure 4C and D; Supplementary Figure 6B and C [See
online supplementary material for a color version of this
figure.]) and no difference in tumor growth as subcutaneous
explants in vivo (P = .17) (Figure 4E and F). Furthermore,
there was no difference in levels of Ki67 or Cleaved Caspase
3 between the groups (Supplemental Figure 7 [See online
supplementary material for a color version of this figure.]).
In striking contrast, Trim23 knockdown reduced tumor
seeding (metastasis) following intraventricular injection
(Figure 4G and H), supporting its role in tumor metastasis,
rather than primary tumor expansion. This result was verified with two different Trim23 knockdown lines.
Taken together, the proof of concept experiments described in this report make two important points. First, we
establish that the cancer cells most likely to contribute to
MPNST metastasis and reduced patient survival are already present in the primary tumor early during disease
evolution. Second, we demonstrate that MPNST metastatic behavior is regulated by TRIM23, a seminal member
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Supplementary material is available online at NeuroOncology (http://neuro-oncology.oxfordjournals.org/).
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of the TRIM family. Future studies are ongoing to define the
underlying mechanism of action as an initial step towards
targeting this clinically relevant population of cancer cells
and developing biomarkers for disease progression.
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worse overall survival (P = .15), no statistically significant
difference was observed in this small data set (Figure 3B
and C). A larger multi-institutional study will be required
to establish its prognostic utility in this rare cancer. The
polycomb repressive complex 2 (PRC2)/polycomb repressive complex 2 subunit (SUZ12) has recently been shown
to play an important role in MPNST pathogenesis.26,27
Given that PRC2 loss occurs in 60%–70% of MPNSTs and
affects transcriptional regulation, we sought to determine
whether there was a correlation between PRC2 loss and
TRIM23 expression, which could suggest a link between
these events. As a surrogate for PRC2/SUZ12 loss, we performed immunohistochemistry to examine H3K27 me3, a
known downstream target of SUZ12. There was no correlation between these events in this cohort as assessed using
a chi-square test (Table 1; P = .4754). Additionally, there
was no association between H3K27 me3 status and overall
survival (Supplementary Figure 4 [See online supplementary material for a color version of this figure.])
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